XingImaging is a neuroimaging services company specializing in the efficient application of scintigraphic biomarkers in drug development and clinical research for neurodegenerative and neuropsychiatric disorders.
NEW HAVEN, Conn., Jan. 13, 2025 /PRNewswire/ -- XingImaging, a MITRO company, a leader in advanced research imaging and radiopharmaceutical services, is excited to announce the opening of its new state-of-the art research facility in New Haven, Connecticut.
XingImaging is based in New Haven, CT with over 24,000 sq ft. of research space and over 40 staff members. Our team is organized into Clinical, Chemistry, and Imaging Sciences divisions with administrative and project support including Regulatory Affairs, Quality Assurance, Imaging and Data Management Services, Information Technology, and Business Operations.
XingImaging provides services across the pre-clinical and clinical spectrum including radioligand development and manufacturing, design and implementation of Phase 1 to Phase 4 clinical trials, and customized clinical imaging site coordination and management in multi-site imaging studies.
Our strong emphasis is on research using investigational radiotracers with quantitative imaging outcome measures as diagnostic tools and/or for assessing disease mechanism or progression. Our focus is on developing radioligands as tools for human research.
Our research staff has leadership roles in numerous clinical imaging trials and in several research consortiums and international research organizations focused on clinical neuroscience and nuclear medicine aimed at advancing knowledge regarding the causes and developing more effective treatments for neurodegenerative disorders. XingImaging's research facility has the capability to conduct imaging research in a comprehensive yet highly efficient manner.
XingImaging, LLC
55 Church Street, 7th Floor, New Haven, Connecticut 06510, United States
Copyright © 2024 XingImaging, LLC - All Rights Reserved.